First-Year Experiences with the Interagency Guidelines for Drug Donations
(2000; 51 pages)
Table of Contents
View the documentAcknowledgements
View the documentExecutive summary
Open this folder and view contents1. Introduction
Open this folder and view contents2. Sources of information and study methodology
Open this folder and view contents3. Dissemination and uptake of the Guidelines
Close this folder4. Basic characteristics of drug donations
View the documentMagnitude of donations made in the past 12 months
View the documentCost basis of donation value
View the documentPercentage of donations made for emergencies
View the documentPercentage of donations based on specific requests
Open this folder and view contents5. Practical benefits as a result of the Guidelines
View the document6. Drug donations which were hampered, delayed or cancelled
Open this folder and view contents7. Experiences and opinions regarding the 12-month shelf-life requirement
Open this folder and view contents8. Other suggestions to improve the Guidelines
Open this folder and view contents9. How could donation practice be further improved?
View the document10. Summary of recommendations
View the document11. Postscript
View the documentReferences
 

Magnitude of donations made in the past 12 months

The total value of donations reported by the donors in this study was US$ 298 million - 14 industry donors contributed US$ 228 million (76%), 11 non-governmental organizations contributed US$ 68 million (23%) and governmental agencies contributed US$ 3 million (1%). Consolidators represented in this study reported donations totalling US$ 360 million.

There were huge differences in size between amounts donated by the various donors. For example, one pharmaceutical industry donor reported annual donations of US$ 170 million, which is 74% of all industry donors. The four largest donors (with US$ 170, 18, 15 and 11 million) constitute 94% of industry donations. The situation is similar with regard to consolidators. With a reported annual turnover of US$ 148 and 141 million, the two largest consolidators constitute 80% of all consolidators.

Soft loans by the World Bank as well as the many ongoing bilateral drug donations by the Governments of Denmark, the Netherlands, Sweden and other countries are not included in this overview. The former are estimated at about US$ 300 million a year, while the latter are not really known but can be estimated at several tens of millions of dollars per government per year. These are all donations of procured drugs (usually through tender).

to previous section to next section
 

Last updated: May 3, 2013